Peregrine Pharmaceuticals is baffled by the recent results of its non-small cell lung cancer trial – a failure they claim was due to a better-than-expected response in the comparator arm. Yet, the failure throws several clinical programs into uncertainty.
The biotech announced after the market close on Feb. 25 that the Phase III SUNRISE trial would be stopped after...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?